“Who knows how much death and suffering this will cause but that seems of little concern to the corrupt hacks at the FDA.” Admin
One of India’s top health officials made major news last week with an announcement about safety concerns regarding an experimental treatment for COVID-19.
Director-General of the Indian Council of Medical Research Balram Bhargava used a news conference Wednesday to say the pharmaceutical giant Merck’s experimental COVID-19 pill, known as molnupiravir, will not be added to the country’s national treatment protocol, according to The Economic Times.
He cited the “major safety concerns” surrounding this pill for this decision, according to Reuters, including the potential to cause birth defects — technically known as teratogenicity — potential DNA damage — known as multagenicity — and other problems.
Read More: India Makes Huge Announcement About Its National COVID Treatment Protocol
Thanks! Share it with your friends!
Tweet
Share
Pin It
LinkedIn
Google+
Reddit
Tumblr